Formulation and Evaluation of Luteolin-Loaded Nanovesicles: Physicochemical Characterization and Viability Assessment
Overview
Authors
Affiliations
Luteolin (LT) is a natural polyphenol water-insoluble compound. LT-loaded nanovesicles (NVs) were prepared by using the solvent evaporation method. LT-NVs were prepared using cholesterol, phosphatidylcholine, span 60, and labrasol in a different composition. The prepared LT-NVs were evaluated for encapsulation efficiency, in vitro drug release, and permeation study. The optimized LT-NVs were further evaluated for antioxidant activity and cytotoxicity using the lung cancer cell line. LT-NVs showed nanometric size (less than 300 nm), an optimum polydispersibility index (less than 0.5), and a negative zeta potential value. The formulations also showed significant variability in the encapsulation efficiency (69.44 ± 0.52 to 83.75 ± 0.35%) depending upon the formulation composition. The and permeation study results revealed enhanced drug release as well as permeation profile. The formulation LT-NVs (F2) showed the maximum drug release of 88.28 ± 1.13%, while pure LT showed only 20.1 ± 1.21% in 12 h. The release data revealed significant variation ( < 0.001) in the release pattern. The permeation results also depicted significant ( < 0.001) enhancement in the permeation across the membrane. The enhanced permeation from LT-NVs was achieved due to the enhanced solubility of LT in the presence of the surfactant. The antioxidant activity results proved that LT-NVs showed greater activity compared to pure LT. The cytotoxicity study showed lesser IC value from LT-NVs than the pure LT. Thus, it can be concluded that LT-NVs are a natural alternative to the synthetic drug in the treatment of lung cancer.
Luteolin: exploring its therapeutic potential and molecular mechanisms in pulmonary diseases.
Lv J, Song X, Luo Z, Huang D, Xiao L, Zou K Front Pharmacol. 2025; 16:1535555.
PMID: 40012626 PMC: 11861102. DOI: 10.3389/fphar.2025.1535555.
Mahmoud T, Abdelfatah M, Omar M, Hasan O, Wali S, El-Mofty M Pharmaceutics. 2025; 17(1).
PMID: 39861720 PMC: 11769262. DOI: 10.3390/pharmaceutics17010072.
The Recent Development of Luteolin-loaded Nanocarrier in Targeting Cancer.
Kar B, Rout S, Halder J, Mahanty R, Mishra A, Saha I Curr Pharm Des. 2024; 30(27):2129-2141.
PMID: 38963114 DOI: 10.2174/0113816128313713240628063301.
Huang X, Lin K, Liu S, Yang J, Zhao H, Zheng X Front Pharmacol. 2024; 15:1362150.
PMID: 38903985 PMC: 11188438. DOI: 10.3389/fphar.2024.1362150.
Hashemzadeh H, Hanafi-Bojd M, Iranshahy M, Zarban A, Raissi H Sci Rep. 2023; 13(1):2501.
PMID: 36781871 PMC: 9925764. DOI: 10.1038/s41598-023-29237-0.